Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is on a quest to expand immune system stimulation to revolutionize the fight against cancers and infectious diseases. Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis, and other diseases, and the company’s DNA-based immunotherapy technology platform is progressively showing its potential to establish a new paradigm to prevent and treat life-altering diseases, with validating efficacy data from a large controlled phase II study. For more information, visit the company’s website at www.inovio.com.